首页> British Journal of Haematology> Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group

导出原文传递

翻译打印收藏纠错

第一作者： Purroy, Noelia

作者： Purroy, Noelia ^[1] ; Bergua, Juan ^[2] ; Gallur, Laura ^[3] ; Prieto, Julio ^[4] ; Lopez, Luis A. ^[5] ; Sancho, Juan M. ^[6] ; Garcia-Marco, Jose A. ^[7] ; Castellvi, Josep ^[8] ; Montes-Moreno, Santiago ^[9] ; Batlle, Ana ; Gonzalez de Villambrosia, Sonia ; Carnicero, Fernando ; Ferrando-Lamana, Lucia ; Piris, Miguel A. ; Lopez, Andres

作者单位： Hosp Royo Villanova, Dept Haematol, Zaragoza, Spain ^[1] Hosp Univ Marques de Valdecilla, Dept Pathol, IFIMAV, Santander, Spain ^[2] Hosp Univ Vall dHebron, Dept Pathol, Barcelona, Spain ^[3] Univ Autonoma Barcelona, Dept Haematol, Hosp Univ Vall dHebron, VHIR, E-08193 Barcelona, Spain ^[4] Hosp Puerta del Hierro, Dept Haematol, Madrid, Spain ^[5] Hosp Badalona Germans Trias & Pujol, Dept Haematol, Badalona, Spain ^[6] Hosp Univ Marques de Valdecilla, Dept Haematol, Cytogenet Unit, IFIMAV, Santander, Spain ^[7] Hosp San Pedro Alcantara, Dept Pathol, Caceres, Spain ^[8] Hosp San Pedro Alcantara, Dept Haematol, Caceres, Spain ^[9]

关键词 large B-cell lymphoma high-risk patients dose-adjusted-EPOCH-R (etoposide prednisone vincristine cyclophosphamide doxorubicin and rituximab)cell of origin

发布时间 2015-06-30

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交